Skip to main
AXSM

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 53%
Buy 41%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics Inc. demonstrates a strong growth trajectory, evidenced by 3Q sales of $31.6 million, which reflects an increase from the previous quarter, alongside a notable rise in total prescriptions (TRx) to 53,000. The company is expected to achieve cash flow-positive status by 2026, driven by projected revenue growth outpacing operational costs and improving operating margins. Additionally, the increasing market penetration of its lead product, AXS-05, following positive Phase III data and expanding coverage, positions the company favorably for future success in managing central nervous system disorders.

Bears say

The financial outlook for Axsome Therapeutics is negatively impacted by several key risks associated with its product pipeline and market performance. Significant concerns include the potential for lower-than-expected market access for AUVELITY and setbacks in clinical trials for AXS-05 and other candidates, which could hinder the company's growth prospects. Additionally, factors such as competitive pressures and the risk of dilution may further strain the company's ability to achieve projected commercial success and secure necessary approvals.

Axsome Therapeutics (AXSM) has been analyzed by 17 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 41% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 17 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $186.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $186.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.